Startup Dossier
Axoltis Pharma
French BioTech developing innovative therapies for neurodegenerative and neurotraumatic diseases. Its lead candidate, NX210c—a cyclic peptide targeting blood-brain barrier repair, neuroprotection, and neurotransmission—has entered Phase 2 clinical trials in ALS/Lou Gehrig’s disease.
active
Typestartup
SectorBioTech
LocationClermont-Ferrand
About
French BioTech developing innovative therapies for neurodegenerative and neurotraumatic diseases. Its lead candidate, NX210c—a cyclic peptide targeting blood-brain barrier repair, neuroprotection, and neurotransmission—has entered Phase 2 clinical trials in ALS/Lou Gehrig’s disease.
Structural DNA
Legal Name
Axoltis Pharma
SIREN
447817818